Kane Biotech Surpasses Enrollment Target in U.S. Case Series for revyve® Antimicrobial Wound Products

Kane Biotech Inc. announced that it has successfully enrolled 28 participants in its U.S. case series studies evaluating the company’s revyve® Antimicrobial Wound Gel and Spray, surpassing the original target of 25 participants.

“Interest from clinicians and patients in the U.S. case series is encouraging. Revyve products can meaningfully improve outcomes for those suffering from challenging wounds and burns,” said Dr. Robert Huizinga, Interim CEO. 

The studies engage wound care and burn specialists across the United States, with data expected to be presented at leading medical meetings throughout 2025 and 2026. The program is designed to gather real-world evidence on the clinical utility of revyve® in managing challenging wounds.

Kane Biotech is advancing innovative wound care solutions that target biofilms, a major factor contributing to antibiotic resistance and poor wound healing outcomes. Its FDA 510(k)-cleared revyve® Gel and Spray are designed to address both biofilms and wound bacteria, offering a novel approach to improve patient healing and reduce healthcare costs.